List of Studies ( Metabolite:(1S,2S)-3-Oxo-2-pentyl-cyclopentanebutanoic acid)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
|---|---|---|---|---|---|---|---|
| ST000421 | AN000663 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST000421 | AN000665 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST000422 | AN000667 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST000422 | AN000669 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
| ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
| ST002094 | AN003421 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
| ST000046 | AN000076 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
| ST000046 | AN000077 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
| ST000047 | AN000080 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
